Replimune (REPL) stock dips as the FDA plans an advisory committee meeting after accepting the company's marketing ...

Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value. BMO Capital expects the stock to witness a meaningful rally following the exit ...

Based on page view growth over the last 3 trading days Key Takeaways Replimune shares fell 54.2% in three months after the FDA issued a CRL against its RP1 BLA in July. The FDA cited shortcomings in ...

REPL shares soared 85.7% after FDA alignment on RP1 plus Opdivo BLA resubmission plans. Replimune plans to resubmit the BLA in the coming days. The FDA intends to prioritize review. The RP1 plus ...

REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...